Alkermes (ALKS) Receivables (2011 - 2026)
Alkermes' (ALKS) quarterly Receivables came in at $407.6 million in Q1 2026, up 26.69% year-on-year from $321.8 million in Q1 2025, and up 1.95% on a QoQ basis from $399.8 million in Q4 2025.
Alkermes (ALKS) Receivables (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has 16 years of Receivables data on file, last reported at $407.6 million in Q1 2026.
- On a quarterly basis, Receivables rose 26.69% year-over-year to $407.6 million in Q1 2026; TTM through Mar 2026 was $407.6 million, a 26.69% increase from a year earlier, with the FY2025 full-year figure at $399.8 million, up 436.75% from the prior year.
- Receivables for Q1 2026 stood at $407.6 million, up from $399.8 million in the prior quarter.
- Over the last five years, Receivables for ALKS reached as high as $407.6 million in Q1 2026 and fell as low as $1.4 million in Q4 2023.
- Historically, Receivables has averaged $198.3 million across 5 years, with a median of $267.3 million in 2022.
- Across the five-year window, Receivables slumped 98.26% in 2023 and soared 5175.5% in 2024, its largest moves.
- Year by year, Receivables stood at $80.9 million in 2022, then slumped by 98.26% to $1.4 million in 2023, then surged by 5175.5% to $74.5 million in 2024, then soared by 436.75% to $399.8 million in 2025, then rose by 1.95% to $407.6 million in 2026.
- Per Business Quant data, the three most recent Receivables figures were $407.6 million in Q1 2026, $399.8 million in Q4 2025, and $355.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 2.99 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.39 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.51 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 6.46 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 312.00 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.29 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 3.58 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 768.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.15 Bn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | 407.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 407.63 Mn |
| Dec 31, 2025 | 399.83 Mn |
| Sep 30, 2025 | 355.11 Mn |
| Jun 30, 2025 | 2.85 Mn |
| Mar 31, 2025 | 321.75 Mn |
| Dec 31, 2024 | 74.49 Mn |
| Sep 30, 2024 | 370.18 Mn |
| Jun 30, 2024 | 6.98 Mn |
| Mar 31, 2024 | 317.08 Mn |
| Dec 31, 2023 | 1.41 Mn |
| Sep 30, 2023 | 340.46 Mn |
| Jun 30, 2023 | 334.48 Mn |
| Mar 31, 2023 | 16.86 Mn |
| Dec 31, 2022 | 80.93 Mn |
| Sep 30, 2022 | 267.28 Mn |
| Jun 30, 2022 | 32.97 Mn |
| Mar 31, 2022 | 40.42 Mn |
| Dec 31, 2021 | 140.96 Mn |
| Sep 30, 2021 | 292.67 Mn |
| Jun 30, 2021 | 306.15 Mn |